Such factors would have to be protective against thyroid cancer and be more prevalent in the GLP1 receptor agonist group than in the comparator groups, or increase the risk of thyroid cancer and be less prevalent in the GLP1 receptor agonist group than in the comparator groups. This evidence concerns the gene GLP1R and thyroid gland carcinoma.